Update to Osteoporosis Drug Codes Billable on Home Health Claims

MLN Matters Number: MM11846
Related Change Request (CR) Number: 11846
Related CR Release Date: August 7, 2020
Effective Date: January 1, 2021
Related CR Transmittal Number: R10274CP
Implementation Date: January 4, 2021

PROVIDER TYPES AFFECTED

This MLN Matters Article is for Home Health Agencies (HHAs) who bill Medicare Administrative Contractors (MACs) for osteoporosis drugs provided to Medicare beneficiaries.

PROVIDER ACTION NEEDED

CR 11846 adds instructions for billing and payment of additional codes for osteoporosis drugs under the home health benefit. Make sure your billing staffs are aware of these changes.

BACKGROUND

Sections 1861(m) and 1861(kk) of the Social Security Act provide for coverage of Food and Drug Administration (FDA) approved injectable drugs for osteoporosis provided by a Home Health Agency (HHA) to female beneficiaries who meet certain criteria. Initially, the only FDA approved injectable drug for osteoporosis was calcitonin. Effective for dates of services on or after January 1, 2005, Medicare also began covering teriparatide (brand named Forteo), an injectable drug approved by the FDA for use in treating osteoporosis.

Since that time, there have been additional drugs approved for use in treating osteoporosis that would be covered under the Medicare home health benefit if provided by an HHA to eligible female beneficiaries. These include osteoporosis drugs that have the ingredient denosumab (brand names Xgeva and Prolia), romosozumab-aqqg (brand name Evenity) or abaloparatide (brand name, Tymlos). The eligibility criteria for female beneficiaries to get osteoporosis drugs are in the Medicare Benefit Policy Manual, Chapter 7, Section 50.4.3, which is available at https://www.cms.gov/Regulations-and-Guidance/Guidance-Manuals/Downloads/bp102c07.pdf.

The administration of the drug is included in the charge for the skilled nursing visit billed using TOB 032x. The cost of the drug is billed using TOB 034x, using revenue code 0636. These drugs are paid on a reasonable cost basis, using the provider’s submitted charges to make initial payments, which are subject to annual cost settlement.
You may bill:

- Drugs that have the ingredient teriparatide using HCPCS code J3110, if all existing guidelines for coverage under the home health benefit are met. HCPCS code J3110 is defined as 10 mcg. Providers should report 1 unit for each 10 mcg dose provided during the billing period.
- Drugs that have the ingredient denosumab using HCPCS code J0897, if all existing guidelines for coverage under the home health benefit are met. HCPCS code J0897 is defined as 1 mg. Providers should report 1 unit for each 1 mg dose provided during the billing period.
- Drugs that have the ingredients romosozumab-aqqg using HCPCS code J3111, if all existing guidelines for coverage under the home health benefit are met. HCPCS code J3111 is defined as 1 mg. Providers should report 1 unit for each 1 mg dose provided during the billing period.
- Drugs that have the ingredient abaloparatide using HCPCS code J3590 (unclassified biologics), if all existing guidelines for coverage under the home health benefit are met. As an unclassified code, HCPCS code J3590 does have not a standard definition for units. Providers should report 1 unit for each 80 mcg dose provided during the billing period.

**ADDITIONAL INFORMATION**


If you have questions, your MACs may have more information. Find their website at [http://go.cms.gov/MAC-website-list](http://go.cms.gov/MAC-website-list).

**DOCUMENT HISTORY**

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>August 7, 2020</td>
<td>Initial article released.</td>
</tr>
</tbody>
</table>

Disclaimer: Paid for by the Department of Health & Human Services. This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2019 American Medical Association. All rights reserved.

Copyright © 2013-2020, the American Hospital Association, Chicago, Illinois. Reproduced by CMS with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816. You may also contact us at ub04@healthforum.com.
The American Hospital Association (the “AHA”) has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.